ProKidney Corp. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 21, 2024. ProKidney is a clinical-stage biotechnology company developing rilparencel (REACT), an investigational autologous kidney-cell therapy. It had no approved products and generated no product revenue.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $106.7 million | $82.1 million |
| General and administrative expense | $44.8 million | $70.9 million |
| Total operating expense / operating loss | $151.5 million | $153.0 million |
| Net loss before noncontrolling interest | $135.4 million | $148.1 million |
| Net loss attributable to Class A shareholders | $35.5 million | $108.0 million* |
| Net cash used in operating activities | $90.1 million | $77.1 million |
*The 2022 Class A shareholder loss and per-share figure reflect only the period after the July 2022 business combination, so they are not directly comparable to full-year 2023.
- Liquidity: At year-end, cash and cash equivalents were $60.6 million and short-term marketable securities were $302.3 million, totaling approximately $363.0 million. Management estimated these resources would fund operations and capital expenditures into the fourth quarter of 2025, based on its current plan and assumptions.
- Cash flow and investment: Investing activities used $330.0 million, primarily reflecting purchases of marketable securities and $25.5 million for a Greensboro facility and land. Financing activities used $9.6 million, principally for a share repurchase. The reported $429.6 million decrease in cash largely reflects investment of cash in marketable securities, not operating burn alone.
- Debt and obligations: The filing reports no outstanding borrowings at year-end. Lease liabilities totaled $4.4 million; income taxes payable totaled approximately $2.0 million, current and noncurrent combined. Revenue margins are not applicable because the company has no product sales.
- Balance sheet: Total assets were $420.6 million and total liabilities were $29.2 million. Redeemable noncontrolling interest was $1,494.7 million, and shareholders’ deficit was $1,103.4 million; ProKidney consolidates PKLP while outside holders own most of its economic interest.
Material changes versus the prior period
- R&D expense increased $24.6 million, primarily from Phase 3 trial activity, hiring, compensation and expanded facilities; a $14.1 million reduction in prior-period equity-based service costs partly offset the increase.
- G&A expense decreased $26.1 million, mainly because 2022 included substantial equity compensation and business-combination costs. Higher public-company legal and professional costs, hiring and severance partly offset the reduction.
- Interest income increased to $22.1 million from $6.0 million, reflecting higher average cash and investment balances and higher interest rates.
- Operating cash use increased by approximately $13.0 million. The company also acquired a 210,000-square-foot Greensboro facility and approximately 22 acres in 2023 in preparation for potential commercial manufacturing.
- In November 2023, ProKidney repurchased 7,256,367 Class A shares for approximately $9.5 million, or $1.309 per share; it was not part of a previously announced repurchase program.
Outlook, clinical program and risks
- Clinical plans: ProKidney anticipated submitting amendments to PROACT 1 in early 2024 and resuming enrollment in the first half of 2024. It expected PROACT 2 enrollment to begin in the second half of 2024, with site activations during 2024. These are management expectations, not assurances.
- Manufacturing pause: A 2023 audit by the company’s contracted Qualified Person identified documentation deficiencies in quality-management systems required for EU product release. Manufacturing was paused while the company addressed the findings and prepared for Phase 3 and potential commercial standards. The filing said the pause was not prompted by safety events and that manufacturing was planned to resume by the end of June 2024.
- Clinical evidence: November 2023 RMCL-002 interim findings suggested potential kidney-function preservation, particularly among higher-risk Stage 4 patients, but were preliminary and subject to further review. Final RMCL-002 results were expected in the first half of 2024. Earlier studies reported procedure-related and renal serious adverse events; efficacy and safety remain to be established in controlled Phase 3 trials.
- Development and funding risks: The company expects continued substantial losses and says it will need additional capital to complete development. Its January 2024 at-the-market agreement permits sales of up to $100 million of Class A shares, which could dilute shareholders. The runway estimate depends on assumptions and may be affected by spending, trial timing, manufacturing remediation and market conditions.
- Other risks: Key uncertainties include Phase 3 enrollment and outcomes, regulatory approval, manufacturing quality and capacity, patient-specific supply-chain execution, reimbursement and market acceptance, competition from established CKD therapies, and dependence on third parties. No material litigation was reported. Management said disclosure controls and internal control over financial reporting were effective at year-end; the auditor issued an unqualified opinion on the financial statements and did not attest to internal-control effectiveness. No material cybersecurity incidents were reported.
Important facts for investors to verify
- Whether manufacturing restarted on schedule and the EU quality-system documentation findings were resolved.
- Actual PROACT 1 amendment, enrollment-resumption and PROACT 2 startup timelines, as well as subsequent recruitment progress.
- Final RMCL-002 results and later controlled-trial evidence, including efficacy and procedure-related safety outcomes.
- Cash, short-term investments and operating cash use in subsequent filings against management’s fourth-quarter 2025 runway estimate; also track any ATM share sales or other financing.
- The economic and voting effects of PKLP’s redeemable noncontrolling interest, Class B shares, potential unit exchanges and the tax receivable agreement. As of March 21, 2024, 61.6 million Class A and 167.7 million Class B shares were outstanding.